- Home
- ALNY vs WCN Comparison
ALNY vs WCN Comparison
Compare ALNY & WCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- WCN
- Stock Information
- Founded
- ALNY 2002
- WCN 1997
- Country
- ALNY United States
- WCN Canada
- Employees
- ALNY N/A
- WCN N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- WCN Power Generation
- Sector
- ALNY Health Care
- WCN Utilities
- Exchange
- ALNY Nasdaq
- WCN Nasdaq
- Market Cap
- ALNY 42.9B
- WCN 48.9B
- IPO Year
- ALNY 2004
- WCN 1998
- Fundamental
- Price
- ALNY $339.80
- WCN $189.26
- Analyst Decision
- ALNY Strong Buy
- WCN Strong Buy
- Analyst Count
- ALNY 25
- WCN 15
- Target Price
- ALNY $347.75
- WCN $213.47
- AVG Volume (30 Days)
- ALNY 878.5K
- WCN 1.5M
- Earning Date
- ALNY 07-31-2025
- WCN 07-23-2025
- Dividend Yield
- ALNY N/A
- WCN 0.67%
- EPS Growth
- ALNY N/A
- WCN N/A
- EPS
- ALNY N/A
- WCN 2.48
- Revenue
- ALNY $2,348,099,000.00
- WCN $9,234,003,000.00
- Revenue This Year
- ALNY $32.73
- WCN $7.94
- Revenue Next Year
- ALNY $31.50
- WCN $7.09
- P/E Ratio
- ALNY N/A
- WCN $76.34
- Revenue Growth
- ALNY 17.21
- WCN 9.65
- 52 Week Low
- ALNY $205.87
- WCN $169.36
- 52 Week High
- ALNY $345.98
- WCN $201.66
- Technical
- Relative Strength Index (RSI)
- ALNY 66.90
- WCN 56.77
- Support Level
- ALNY $323.74
- WCN $185.83
- Resistance Level
- ALNY $332.19
- WCN $191.91
- Average True Range (ATR)
- ALNY 8.07
- WCN 3.13
- MACD
- ALNY 0.53
- WCN 1.10
- Stochastic Oscillator
- ALNY 83.03
- WCN 76.73
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About WCN Waste Connections Inc.
Waste Connections is the third-largest integrated provider of traditional solid waste and recycling services in the North America, operating 113 active landfills (20 are exploration and production waste landfills and 16 are nonmunicipal waste landfills), 163 transfer stations, and 89 recycling operations. The firm serves residential, commercial, industrial, and energy end markets. Waste Connections entered the Canadian market with its 2016 merger with Progressive Waste. In 2024, 14% of consolidated revenue was generated from the firm's Canadian segment.